Skip to content

Cardiac Tumors Interventional (Radio Frequency/Laser Ablation)Therapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02815553
Acronym
CTIH
Enrollment
10
Registered
2016-06-28
Start date
2016-04-30
Completion date
2022-08-31
Last updated
2022-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Tumors

Brief summary

Currently, surgical removal remains the main clinical treatment for cardiac tumor patients. However, part of tumors are hard to completely resect. Also, as thoracoscopic surgeries induce great operation trauma, some patients cannot tolerate or do not will to take the operation. Therefore, new methods and techniques are in urgent need. Our center have a 12-year experience of intervention treatment for solid tumors and has conducted several animal experiments to verify the effectiveness of transthoracic puncture ablation and radiofrequency ablation for ventricular muscle. The purpose of this study is to conduct new method of direct transthoracic cardiac tumor-targeted Radiofrequency Ablation (RFA) or Laser induced Interstitial Thermotherapy (LITT), make minimally invasive treatment plans for cardiac tumor patients, and verify the safety and validity of intervention treatment in long term.

Interventions

PROCEDUREDirect Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy
PROCEDUREDirect Transthoracic Cardiac Tumor Laser Ablation Therapy

Sponsors

Xijing Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cardiac tumors not suitable for surgical removal * Subject has significant clinical symptoms or obstruction (or progressive obstruction increase) in inflow or outflow tracts shown in imaging evidence * Cardiac tumors in ventricular chambers, myocardium, or pericardium * Subject who cannot tolerate thoracoscopic removal or volunteer for the operation * Subject Over 12 years old

Exclusion criteria

* Subject who has other cardiac diseases must receive surgical removal * Subject has end-stage heart failure * Subject has poor physical conditions and cannot tolerate the operation

Design outcomes

Primary

MeasureTime frameDescription
Mortality24 months
Tumor size24 monthsIf the maximum tumor size increases, the symptom gets deteriorated; If the maximum tumor size decreases, the symptom gets relieved.
Quantification of obstructive severity24 monthsInvestigators use the peak velocity and of stenosis (by echocardiography) to quantify obstructive severity caused by the tumor. If the peak velocity increases, the symptom gets deteriorated; if the peak velocity decreases, the symptom gets relieved.

Secondary

MeasureTime frameDescription
Quantification of cardiac function24 monthsInvestigators use ejection fraction(EF) to quantify the cardiac function. If EF is higher after the operation, the cardiac function gets recovered; if EF is lower after the operation,the cardiac function does't get recovered.
Quantification of tumor blood perfusion24 monthsInvestigators use contrast-enhanced ultrasonography to quantify tumor blood perfusion. If there is no perfusion observed, the therapy is successful;if there is perfusion, the therapy is ineffective.

Countries

China

Contacts

Primary ContactLiwen Liu, MD
liuliwencrt@hotmail.com86-13571975528

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026